NT5C2, 5'-nucleotidase, cytosolic II, 22978

N. diseases: 149; N. variants: 24
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0004352
Disease: Autistic Disorder
Autistic Disorder
0.010 GeneticVariation disease BEFREE Therefore, this family-based association study was performed in 640 Chinese Han autism trios to investigate the association between autism and 7 SNPs with genome-wide significance in previous GWAS (rs4307059 near MSNP1AS, rs4141463 in MACROD2, rs2535629 in ITIH3, rs11191454 in AS3MT, rs1625579 in MIR137HG, rs11191580 in NT5C2, and rs1409313 in CUEDC2). 30610940 2019
CUI: C0007847
Disease: Malignant tumor of cervix
Malignant tumor of cervix
0.010 Biomarker disease BEFREE We found some of overexpressed genes of CC participated in GMP biosynthetic process. 30841438 2019
CUI: C0017574
Disease: Gingivitis
Gingivitis
0.010 Biomarker disease BEFREE Of critical importance are vascular nitric oxide; nutrition; exercise; weight control and maintaining insulin sensitivity; early treatment of hypertension with attention to effects on erectile function; avoiding sources of oxidative stress such as obesity and smoking; reducing inflammation (e.g. from gingivitis); improving pelvic floor muscle strength; and inhibiting cyclic GMP break-down. 31724458 2019
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia
0.010 Biomarker disease BEFREE In summary, NT5C2 deletion in mice protects against HFD-induced weight gain, adiposity, insulin resistance and associated hyperglycemia. 30803894 2019
CUI: C0023283
Disease: Leishmaniasis, Cutaneous
Leishmaniasis, Cutaneous
0.010 Biomarker disease BEFREE In conclusion, leishmanization using Leishmania major produced under GMP guideline is a valuable tool to protect against CL, there are limitations which need further study. 31525323 2019
CUI: C0042769
Disease: Virus Diseases
Virus Diseases
0.010 Biomarker group BEFREE Cyclic GMP-AMP signalling protects bacteria against viral infection. 31533127 2019
CUI: C0151936
Disease: Disorder of tendon
Disorder of tendon
0.010 Biomarker group BEFREE Twenty patients with a diagnosis of patellar tendinopathy with imaging changes (tendon thickening and disruption of the intratendinous substance at the proximal portion of the patellar tendon) will be randomised in a 1:1 ratio to receive a local injection of either bone-marrow autologous mesenchymal stem cells (MSC), isolated and cultured under GMP at The Institute of Biology and Molecular Genetics (IBGM) (Spain) or P-PRP. 31842921 2019
CUI: C0302592
Disease: Cervix carcinoma
Cervix carcinoma
0.010 Biomarker disease BEFREE We found some of overexpressed genes of CC participated in GMP biosynthetic process. 30841438 2019
CUI: C0376545
Disease: Hematologic Neoplasms
Hematologic Neoplasms
0.010 Biomarker group BEFREE Therefore, these derivatives represent a family of non-nucleos(t)idic cN-II inhibitors with potential usefulness to overcome cancer drug resistance especially in hematological malignancies in which cN-II activity has been described as an important parameter. 30798051 2019
CUI: C1568272
Disease: Tendinopathy
Tendinopathy
0.010 Biomarker disease BEFREE Twenty patients with a diagnosis of patellar tendinopathy with imaging changes (tendon thickening and disruption of the intratendinous substance at the proximal portion of the patellar tendon) will be randomised in a 1:1 ratio to receive a local injection of either bone-marrow autologous mesenchymal stem cells (MSC), isolated and cultured under GMP at The Institute of Biology and Molecular Genetics (IBGM) (Spain) or P-PRP. 31842921 2019
CUI: C1861172
Disease: Venous Thromboembolism
Venous Thromboembolism
0.010 Biomarker phenotype BEFREE The GMP-VTE project is a prospective, multi-center cohort study on individuals with objectively confirmed VTE. 31374513 2019
CUI: C2062441
Disease: Influenza A
Influenza A
0.010 Biomarker disease BEFREE Nasal wash samples from 15 human volunteers challenged with GMP manufactured influenza A/California/04/2009(H1N1) and from 5 naturally infected influenza patients of the 2009 pandemic were deep sequenced using viral targeted hybridization enrichment. 31226666 2019
CUI: C3854629
Disease: Tendon thickening
Tendon thickening
0.010 Biomarker disease BEFREE Twenty patients with a diagnosis of patellar tendinopathy with imaging changes (tendon thickening and disruption of the intratendinous substance at the proximal portion of the patellar tendon) will be randomised in a 1:1 ratio to receive a local injection of either bone-marrow autologous mesenchymal stem cells (MSC), isolated and cultured under GMP at The Institute of Biology and Molecular Genetics (IBGM) (Spain) or P-PRP. 31842921 2019
CUI: C4048328
Disease: cervical cancer
cervical cancer
0.010 Biomarker disease BEFREE We found some of overexpressed genes of CC participated in GMP biosynthetic process. 30841438 2019
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.010 Biomarker disease BEFREE A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure. 29226471 2018
CUI: C0023448
Disease: Lymphoid leukemia
Lymphoid leukemia
0.010 GeneticVariation disease BEFREE Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia. 29990496 2018
CUI: C0023860
Disease: Listeriosis
Listeriosis
0.010 AlteredExpression disease BEFREE The results of this study suggest that elevated c-di-GMP levels decrease the activity of the coordinator of metabolism and virulence, CodY, possibly via lower GTP levels, and that decreased CodY activity suppresses <i>L. monocytogenes</i> virulence by the decreased expression of the PrfA virulence regulon.<b>IMPORTANCE</b><i>Listeria monocytogenes</i> is a pathogen causing listeriosis, a disease responsible for the highest mortality rate among foodborne diseases. 29229701 2018
CUI: C0030193
Disease: Pain
Pain
0.010 Biomarker phenotype BEFREE Antinociceptive effect of tadalafil in various pain models: Involvement of opioid receptors and nitric oxide cyclic GMP pathway. 29777732 2018
CUI: C0041296
Disease: Tuberculosis
Tuberculosis
0.010 Biomarker disease BEFREE Immune response elicited by two rBCG strains devoid of genes involved in c-di-GMP metabolism affect protection versus challenge with M. tuberculosis strains of different virulence. 29550192 2018
CUI: C0264716
Disease: Chronic heart failure
Chronic heart failure
0.010 Biomarker disease BEFREE A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure. 29226471 2018
CUI: C0334108
Disease: Multiple polyps
Multiple polyps
0.010 Biomarker disease BEFREE Cyclic-GMP-Elevating Agents Suppress Polyposis in <i>Apc</i><sup>Min</sup> mice by Targeting the Preneoplastic Epithelium. 29301746 2018
CUI: C2931822
Disease: Nasopharyngeal carcinoma
Nasopharyngeal carcinoma
0.010 Biomarker disease BEFREE The first commercialized oncolytic virus product in the world, Oncorine (H101), developed by Shanghai Sunway Biotech Co., Ltd since 1999, was approved by Chinese SFDA in November, 2005 for nasopharyngeal carcinoma in combination with chemotherapy after the phase III clinical trial, and finally acquired GMP certificate in August, 2006. 29189159 2018
Leukoencephalitis, Acute Hemorrhagic
0.010 AlteredExpression disease BEFREE Phenotypic analyses confirmed changes in the expression of virulence factors, the production of AHL signal molecules and the biosynthesis of different biofilm matrix components upon altered c-di-GMP levels. 28463102 2017
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.010 Biomarker phenotype BEFREE Synergistic Interaction of a Gabapentin- Mangiferin Combination in Formalin-Induced Secondary Mechanical Allodynia and Hyperalgesia in Rats Is Mediated by Activation of NO-Cyclic GMP-ATP-Sensitive K<sup>+</sup> Channel Pathway. 28940250 2017
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis
0.010 Biomarker disease BEFREE Development, functional characterization and validation of methodology for GMP-compliant manufacture of phagocytic macrophages: A novel cellular therapeutic for liver cirrhosis. 28673774 2017